Page last updated: 2024-10-24

chloroquine and Proteinuria

chloroquine has been researched along with Proteinuria in 13 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-199011 (84.62)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abud-Mendoza, C1
de la Fuente, H1
Cuevas-Orta, E1
Baranda, L1
Cruz-Rizo, J1
González-Amaro, R1
SHINOHARA, M1
KOSAKA, M1
SUZUKI, T1
TSUNOKAKE, H1
TSUJI, S1
SHEARN, MA1
OTANI, H1
YAMAMOTO, H1
HIRASAWA, S1
BETSUYAKU, I1
ITO, N1
YACHI, A1
Scotti da Silva-Colombeli, A1
Falkenberg, M1
Poels, LG1
van Niekerk, CC1
Pennings, L1
Agterberg, J1
van Elven, EH1
Zweiman, B1
Kornblum, J1
Cornog, J1
Hildreth, EA1
Campbell, CH1
Holiday, J1
Biggs, JC1
Backhouse, TC1
Missmahl, HP2
Brass, H1
Lapp, H1
Heintz, R1
Tarejew, EM1
Poljanzewa, LR1
Muchin, NA1
Mosgowa, LA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis[NCT00302952]Phase 264 participants (Actual)Interventional2007-11-06Terminated (stopped due to Slow enrollment &Study Drug Expiration (Target: 40 randomized participants /arm))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84

Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Interventionmg/L (Mean)
Lovastatin 80 mg-0.4
Placebo-0.3

Adjusted Mean Change From Baseline in Serum Anti-cyclic Citrullinated Peptide (Anti-CCP) by ELISA (ELISA: Enzyme-linked Immunosorbent Assay)

Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was <8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline ( Day 0), Day 84 (Wk 12)

InterventionIU/mL (Mean)
Lovastatin 80 mg16.3
Placebo-1.0

Adjusted Mean Change From Baseline in Serum IgM Rheumatoid Factor by ELISA (ELISA: Enzyme-linked Immunosorbent Assay)

Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was <0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

InterventionIU/mL (Mean)
Lovastatin 80 mg-5.4
Placebo2.8

Adjusted Mean Change From Baseline in the Disease Activity Score Using C-reactive Protein (DAS28-CRP) on Day 84

The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (>5.1=high disease activity; 3.2-<=5.1=moderate disease activity; <=3.2=low disease activity; <2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0) to Day 84 (Wk 12)

InterventionScores on a scale (Mean)
Lovastatin 80 mg-0.5
Placebo-0.5

Change From Baseline in CPK at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

InterventionU/L (Mean)
Lovastatin 80 mg-2.4
Placebo8.0

Change From Baseline in Hematocrit (Hct) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Intervention% of packed red blood cells by volume (Mean)
Lovastatin 80 mg-0.5
Placebo-0.5

Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Interventionpg (Mean)
Lovastatin 80 mg-0.4
Placebo0.0

Change From Baseline in Mean Corpuscular Volume (MCV) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

InterventionfL (Mean)
Lovastatin 80 mg-0.4
Placebo0.7

Change From Baseline in Red Cell Distribution Width (RDW) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Intervention% of mean corpuscle volume (Mean)
Lovastatin 80 mg-0.4
Placebo0.2

Percentage of Participants Meeting ACR20 Response Criteria at Day 84 (ACR: American College of Rheumatology)

Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis. (NCT00302952)
Timeframe: Day 84 (Wk 12)

InterventionPercentage of participants (Number)
Lovastatin 80 mg29.0
Placebo40.0

Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Interventiong/dL (Mean)
AlbuminTotal ProteinHemoglobinMCHC
Lovastatin 80 mg0.00.0-0.3-0.3
Placebo0.10.1-0.3-0.4

Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
InterventionU/L (Mean)
Alkaline PhosphataseALTAST
Lovastatin 80 mg-3.0-1.8-1.2
Placebo0.40.70.8

Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Intervention10^3/uL (Mean)
WBCNeutrophilsBandsLymphocytesMonocytesEosinophilsBasophilsPlatelet CountReticulocytes
Lovastatin 80 mg0.10.20.0-0.10.10.00.0-8.2-4.7
Placebo-0.4-0.60.00.10.00.00.0-5.60.0

Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Interventionmmol/L (Mean)
PotassiumSodiumChlorideTotal CO2
Lovastatin 80 mg0.0-0.2-0.10.7
Placebo0.0-0.20.5-0.5

Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Interventionmg/dL (Mean)
Total BilirubinCreatinineBUNPhosphorusCalciumGlucose
Lovastatin 80 mg0.00.0-0.40.00.0-4.3
Placebo0.10.0-0.50.00.0-1.2

Reviews

1 review available for chloroquine and Proteinuria

ArticleYear
[Amyloidosis in chronic rheumatic diseases].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1968, Volume: 74

    Topics: Adult; Aged; Amyloidosis; Arthritis, Rheumatoid; Biopsy; Chloroquine; Chronic Disease; Collagen Dise

1968

Trials

1 trial available for chloroquine and Proteinuria

ArticleYear
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
    Lupus, 2003, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation;

2003

Other Studies

11 other studies available for chloroquine and Proteinuria

ArticleYear
[Pregnancy toxemias, with special reference to the effect of chloroquine diorotate (Kidola) on proteinuria].
    [Sanfujinka chiryo] Obstetrical and gynecological therapy, 1963, Volume: 6

    Topics: Chloroquine; Female; Pre-Eclampsia; Pregnancy; Proteinuria; Toxemia

1963
[ON PROTEINURIA].
    Naika. Internal medicine, 1963, Volume: 12

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Chloroquine; Diagnosis, Differential; Humans;

1963
NORMOCHOLESTEROLEMIC NEPHROTIC SYNDROME OF SYSTEMIC LUPUS ERYTHEMATOSUS.
    The American journal of medicine, 1964, Volume: 36

    Topics: Adolescent; Body Weight; Chloroquine; Cholesterol; Humans; Hypercholesterolemia; Lupus Erythematosus

1964
[Pathophysiological studies on serum and urinary protein pattern with reference to the influence of chloroquine-diorotate (Kidola) on nephropathy].
    Naika hokan. Japanese archives of internal medicine, 1962, Volume: 9

    Topics: Chloroquine; Humans; Kidney Diseases; Mucoproteins; Orotic Acid; Proteinuria; Serum Albumin

1962
Analytical interferences of drugs in the chemical examination of urinary protein.
    Clinical biochemistry, 2007, Volume: 40, Issue:13-14

    Topics: Chloroquine; Ciprofloxacin; Clinical Laboratory Techniques; Humans; Pharmaceutical Preparations; Pro

2007
Plasmodium berghei: formation of secondary immune complexes in hyperimmune mice.
    Experimental parasitology, 1977, Volume: 43, Issue:1

    Topics: Animals; Antigen-Antibody Complex; Antigens; Chloroquine; Complement System Proteins; Immunoglobulin

1977
The prognosis of lupus nephritis. Role of clinical-pathologic correlations.
    Annals of internal medicine, 1968, Volume: 69, Issue:3

    Topics: Adrenocorticotropic Hormone; Blood Urea Nitrogen; Chloroquine; Follow-Up Studies; Histological Techn

1968
Chloroquine-resistant Falciparum malaria acquired in Vietnam.
    The Medical journal of Australia, 1973, Oct-13, Volume: 2, Issue:15

    Topics: Acute Kidney Injury; Adolescent; Adult; Blood Cell Count; Chloroquine; Dapsone; Drug Resistance, Mic

1973
[Long term treatment of chronic glomerulonephritis, clinical course and results of renal biopsies].
    Archiv fur klinische Medizin, 1969, Volume: 216, Issue:4

    Topics: Acetates; Adolescent; Adult; Azathioprine; Biopsy; Blood Pressure; Chloroquine; Female; Glomerulonep

1969
[Amyloidosis in ankylosing spondylitis].
    Verhandlungen der Deutschen Gesellschaft fur Rheumatologie, 1969, Volume: 1

    Topics: Amyloidosis; Biopsy; Chloroquine; Diagnosis, Differential; Female; Humans; Kidney Failure, Chronic;

1969
[Trial of resochin therapy in diffuse kidney diseases].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1966, Aug-15, Volume: 21, Issue:16

    Topics: Amyloidosis; Animals; Chloroquine; Chronic Disease; Collagen Diseases; Glomerulonephritis; Humans; K

1966